S.
"Young women and men are waiting longer to have sex , and fewer women and
men report having multiple sexual partners compared to the national survey
carried out five years ago," said Major General (Retired) Herman C.

2010 mycobacterial

The primary endpoint
is the amount of HIV-1 viral load detected in the blood.
"New research brought to light in the last several weeks has revealed the
possibility of a new and more lethal strain of HIV in the United States that
does not respond to existing antiretroviral medicines," added Keledjian.com.

Report: Seven Percent of Tanzanians Infected with HIV; Rate Reaches as High as 13 Percent in Some Urban Areas

The 1999 survey asked a nationally representative
sample of women and men questions about HIV knowledge and sexual practices but
did not conduct HIV testing.

neurodevelopmental reproductive

The proportion of men
with multiple sexual partners also fell from 27 percent to 20 percent in
2003-04.

mycobacterial deafness

AZUSA, Calif.
(OTC Bulletin Board: VRAL), a drug development company developing a biological
therapy for the treatment of HIV infection, announced today that it has
completed patient enrollment in its South African Phase III trial of VGV-1 for
the treatment of HIV-1. The Company's lead drug candidate,
VGV-1, is a treatment for HIV infection and AIDS that has been studied in four
human clinical trials outside of the U. where it is in late -stage clinical
development. Lupogo,
the Executive Chairman of TACAIDS.

ngos reproductive

3 percent
of men.

adolescent neurodevelopmental

7 percent of women are HIV positive compared to 6. Compared with 1999, women reported
delaying first sex by almost a full year in the THIS.

tb tuberculosis

The 2003-2004 Tanzania HIV/AIDS Indicator Survey (THIS) includes results
of interviews and HIV blood tests from a nationally representative sample of
more than 12,000 women and men aged 15-49.
But the report showed knowledge of HIV transmission and prevention as well
as safer sexual behavior increasing in Tanzania. For example, the proportion
of women who knew that mosquito bites do not transmit HIV increased from
54 percent in the 1999 Tanzania Reproductive and Child Health Survey to
71 percent in the THIS.
Safer sexual behavior also increased.

onchocerciasis malaria

, Viral Genetics, Inc. is a drug discovery and development company based in
southern California developing treatments for infectious disease, autoimmune
disease and immunological deficiency. Agency for International Development (USAID) and the
Development Cooperation of Ireland.

neurodevelopmental ngos

Alternatives to antiretroviral
treatments , such as VGV-1 and other immune-based therapies, are being
developed to fight the virus by boosting the immune system. Infection rates also varied widely in
different regions.
The survey showed that HIV infection was associated with alcohol use and
the number of sexual partners.

2010 deafness

Viral Genetics, Inc. VGV-1 and TNP
are not approved by the US Food and Drug Administration or by any comparable
regulatory agencies elsewhere in the world.
believes that the forward-looking statements and underlying assumptions
contained therein are reasonable, any of the assumptions could be inaccurate,
including the ability of Viral Genetics, Inc.

onchocerciasis hoping

Originally, Viral
Genetics had planned to enroll 80 patients in the trial but increased the
number to 135 after the addition of two additional trial sites.
"This makes the development of new treatment options that control HIV without
antiretroviral drugs even more critical. In light of the
significant uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by the Company or any other person that the objectives and
plans of the Company will be achieved.

impoverished amref

"
The South African trial is expected to be completed in the fourth calendar
quarter of 2005, and the Company intends to disclose the results thereafter. Prevalence among
women then rose steadily , peaking at 13 percent for women age 30 to 34.
The Tanzania Commission for AIDS (TACAIDS) initiated the THIS, which was
funded by the U.

blindness tb

, to obtain adequate financing
sufficient to meet its business objectives on reasonable terms and conditions,
and therefore, there can be no assurance that the forward-looking statements
included in this release will prove to be accurate. Iringa and Mbeya have the highest prevalence rate, with
13 percent of men and women HIV positive.

mycobacterial malaria

Tanzanians living in cities were twice as likely to be infected with HIV
as their neighbors in rural areas. Women with two
or more extramarital partners in the past year were two times more likely to
be infected than those without.

neurodevelopmental allafrica

Viral Genetics Inc. Completes Patient Enrollment for South African Phase III Trial of VGV-1 for the Treatment of HIV-1

About Viral Genetics, Inc."
Despite increases in knowledge, most Tanzanians were unaware that
mother-to-child transmission of HIV can be prevented.

tuberculosis ophthamologists

VGV-1 has demonstrated safety in previous human
clinical trials and is believed to suppress HIV-1 viral load in patients. To date, the Company has
conducted four human clinical trials of VGV-1 involving more than 80 patients
with varying degrees of viral load, immunological competency, clinical
condition and treatment history. "These changes are good news and suggest
that our HIV prevention programs are bearing fruit.

amref allafrica

VGV-1 is in the pre-clinical stage of development in the U.
For more information, visit http://www.
Prevalence is as high as 13 percent in some urban areas. THIS is the first survey in
Tanzania to conduct HIV testing through anonymous, voluntary blood tests on a
representative sample of the population. HIV
infection among men was lower than among women until age 35 to 39 and then
peaked at 12 percent at age 40 to 44.

empowers adolescent

The Company
may add additional patients subject to pending pre-enrollment screening. While Viral Genetics, Inc. Most women get infected between ages 20 and 34.

onchocerciasis africana

The
primary endpoint of this trial is the effect of VGV -1 on the amount of virus
in the blood or "viral load.viralgenetics. DAR ES SALAAM, Tanzania, Tanzania continues to
battle high HIV infection rates with 7 percent of adult men and women now
infected , according to the new Tanzania HIV/AIDS Indicator Survey (THIS). Only about 17 percent
of women and men surveyed knew that if an infected woman takes anti-retroviral
therapy (ART) during pregnancy and breastfeeding, she can reduce the risks of
passing the virus to her child.

allafrica onchocerciasis

" The primary goal of the multi-center, randomized,
double-blind, placebo-controlled study is to monitor the safety , efficacy and
immunological function of VGV-1.

This news release contains forward-looking statements that involve risks
and uncertainties associated with clinical development, regulatory approvals,
and other risks described by Viral Genetics, Inc. Among 15 to 19 year
olds, about 2 percent of men and women were HIV positive.

tuberculosis mycobacterial

"
Prior to the initiation of the trial, the Medicines Control Council of
South Africa approved and designated the study "Phase III Assessment of Safety
and Efficacy of Thymus Nuclear Protein Injections for treating stage CDC-2
HIV-1 infected patients .

tb newsfeed

from time to time in its
periodic reports with the Securities and Exchange Commission.

adolescent blindness

"
"We will critically evaluate the clinical effects of VGV-1 on HIV-1
infection during a time that the AIDS epidemic continues to spread throughout
the world," said Haig Keledjian, chairman and chief executive officer, Viral
Genetics.S.
The survey showed women slightly more likely to have HIV infection than
men. In Dar es Salaam, 11 percent of
adults were infected with HIV. Women using alcohol during their last sexual
encounter were more likely to have HIV than those who did not.

neurodevelopmental tuberculosis

The study design involves treatments of
VGV-1 or placebo for 51 days with 240 days of follow -up. Overall, 7.S.

helina africana

"With the completed enrollment of 135 patients, we've reached a
crucial milestone that we believe will ultimately provide the safety and
efficacy data necessary to further advance VGV-1 in South Africa and, it is
hoped, beyond.

About VGV-1
VGV-1 is an investigational immune-based therapy for HIV infection and
AIDS that is extracted from mammalian thymus tissue, processed and
administered through intramuscular injections. Previous data has indicated a marked
decrease in HIV viral load with no significant side effects.

The Tanzania National Bureau of
Statistics conducted the survey with technical assistance from the MEASURE DHS
project led by ORC Macro in Calverton , Maryland.

ophthamologists mycobacterial